Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-09-19
2006-09-19
Chism, B. Dell (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S002600, C530S313000, C530S328000, C530S398000
Reexamination Certificate
active
07109171
ABSTRACT:
Methods for treating FSH related conditions, such as prostatic intraepithelial neoplasia, pedophilia, infertility, or vaginal bleeding, with GnRH antagonists are disclosed. The methods of the invention generally feature administering to a subject a GnRH antagonist suitable for in vivo administration and able to reduce both plasma FSH and LH levels in a subject, in an amount or in a formulation effective to reduce plasma FSH levels in the subject to a symptom alleviating level. In vitro fertilization and male contraceptive methods are also provided.
REFERENCES:
patent: 5470947 (1995-11-01), Folkers et al.
patent: 5821230 (1998-10-01), Jiang et al.
patent: 5843901 (1998-12-01), Roeske
patent: 5968895 (1999-10-01), Gefter et al.
patent: WO 97/44037 (1997-11-01), None
Cook et al. 2000, The Oncologist vol. 5, pp. 162-168.
Behre, H.M. et al. “Sustained suppression of serum LH, FSH and testosterone and increase of high-density lipoprotein cholesterol by daily injections of the GnRH antagonist cetrorelix over 8 days in normal men”Clinical Endocrinology40:241-248 (1994).
Menon, M. et al. “Abarelix (PPI-149), a Novel and Potent GnRH Antagonist, Induces a Rapid and Profound Reduction in Testosterone and PSA in Advanced Prostate Cancer of Patients (PrCa)”Journal of Urology159(5 Suppl.):334 (May 1998).
Newling, D. “PIN I-III: When Sould We Interfere?”European Urology35:504-507 (1999).
Ahokoski, O. et al. “Biological day-to-day variation and daytime changes of testosterone, follitropin, lutropin and oestradiol-17beta in healthy men” Clinical Chemistry and Laboratory Medicine 36(7):485-91 (1998).
Albertsson-Wikland, K. et al. “Twenty-four-hour profiles of luteinizing hormone, follicle-stimulating hormone, testosterone, and estradiol levels: a semilongitudinal study throughout puberty in healthy boys” Journal of Clinical Endocrinology and Metabolism 82(2):541-9 (1997).
Bablok, I. et al. “Relationship between semen quality improvement after varicocelectomy and preoperative levels of hypophyseal and gonadal hormones” International Urology and Nephrology 29(3): 345-9 (1997).
Backer, L.C. et al. “Serum follicle-stimulating hormone and luteinizing hormone levels in women aged 35-60 in the U.S. population: the Third National Health and Nutrition Examination Survey (NHANES III, 1988-1994)” Menopause 6(1):29-35 (1999).
Ballauf, A. et al. “Serum leptin and gonadotropin levels in patiens with anorexia nervosa during weight gain” Molecular Psychiatry 4(1):71-5 (1999).
Basu, M. et al. “Pituitary, gonadal and adrenal hormones after prolonged residence at extreme altitude in man” International Journal of Andrology 20(3):153-8 (1997).
Belgorosky, A. et al. “Serum concentrations of follicle stimulating hormone and luteinizing Hormone in normal girls and boys during prepuberty and at early puberty” Journal of Endorcrinological Investigation 19(2):88-91 (1996).
Bhavnani, B.R. et al. “Biologic effects of delta-8-estrone sulfate in postmenopausal women” Journal of the Society for Gynecologic Investigation 5(3):156-60 (1998).
Bondanelli, M. et al. “Effect of delta-opioid receptor agonist deltorphin on circulating concentrations of luteinizing hormone and follicle stimulating hormone in healthy fertile women” Human Reproduction 13(5):1159-62 (1998).
Brennemann, W. et al. “Pretreatment follicle-stimulating hormone: a prognostic serum marker of spermatogenesis status in patients treated for germ cell cancer” The Journal of Urology 159(6):1942-6 (Jun. 1998).
Check, J. H. et al. “A study to determine whether serum follicle-stimulating hormone can be a marker for ovarian hyperresponse to follicle-maturing drugs for in vitro fertilization” Gynecologic and Obstetric Investigation 43(4):242-4 (1997).
Chia, S.E. et al. “Endocrine profiles of male workers with exposure to trichloroethylene” American Journal of Industrial Medicine 32(3):217-22 (1997).
Christin-Maitre, S. et al. “Homologous in vitro bioassay for follicle-stimulating hormone (FSH) reveals increased FSH biological signal during the mid- to late luteal phase of the human menstrual cycle” Journal of Clinical Endocrinology and Metabolism 81(6):2080-8 (1996).
Crottaz, B. et al. “Normogonadotropic primary amenorrhea in a growth hormone-deficient woman with ectopic posterior pituitary: gonadotropin pulsatility and follicle-stimulating hormone bioactivity” Journal of Endocrinological Investigation 19(1):48-53 (1996).
de Souza, C.J.H. et al. “Incipient ovarian failure associated with raised levels of follicle stimulating hormone and reduced levels of inhibin A in older sheep” Human Reporoduction 13(11):3016-22 (1998).
de Ziegler, D. et al. “Synchronization of endogenous and exogenous FSH stimuli in controlled ovarian hyperstimulation (COH)” Human Reproduction 13(3):561-4 (1998).
Demkow, T. et al. “Sperm, LH FSH, testosterone evaluation in patients with testicular cancer. Preliminary study” Ginekologia Polska 69(6):405-9 (1998).
Derksen, J.G.M. et al. “The effect of hysterectomy and endometrial ablation on follicle stimulating hormone (FSH) levels up to 1 year after surgery” Maturitas 29(2):133-8 (1998).
Dirnhofer, S. et al. “Coexpression of gonadotropic hormones and their corresponding FSH- and LH/CG-receptors in the human prostate” The Prostate 35(3):212-20 (1998).
Farhi, J. et al. “Early prediction of ovarian multifollical response during ovulation induction in patients with polycystic ovary syndrome” Fertility and Sterility 67(3):459-62 (1997).
Galtier-Dereure, F. et al. “Ovarian reserve test with the gonadotrophin-releasing hormone agonist buserelin: correlation with in-vitro fertilization outcome” Human Reporoduction 11(7):1393-8 (1996).
Gordon, W. Jr. e al. “A study of reproductive function in patients with seminoma treated with radiotherapy and orchidectomy: (SWOG-8711). Southwest Oncology Group” Interntaional Journal of Radiation Oncology, Biology, Physics 38(1):83-94 (1997).
Greenman, Y. et al. “The use of beta-subunits of gonadotrophin hormones in the follow-up of clinically non-functioning pituitary tumours” Clinical Endocrinology 49(2):185-90 (1998).
Harris, P.E. “Biochemical markers for clinically non-functioning pituitary tumours” Clinical Endocrinology 49(2):163-4 (1998).
Illingworth, P.J. et al. “Inhibin-B: a likely candidate for the physiologically important form of inhibin in men” Journal of Clinical Endocrinology and Metabolism 81.(4):1321-5 (1996).
Jensen, T.K. et al. “Inhibin B as a serum marker of spermatogenesis: correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men” Journal of Clinical Endocrinology and Metabolism 82(12):4059-63 (1997).
Kerdelhue, B. et al. “Stimulatory effect of a specific substance P antagonist (RPR 100893)of the human NK1 receptor on the estradiol-induced LH and FSH surges in the ovariectomized cynomolgus monkey” Journal of Neuroscience Research 50(1): 94-103 (1997).
Komorowski, J. et al. “Effects of thyrotropin, follicle stimulating hormone and luteinizing hormone on sIL-2R in vitro secretion from human peripheral blood mononuclear cells” CYTOBIOS 93(372):43-8 (1998).
Kovcin, V.N. et al. “Serum gonadotropin levels in patients with germ-cell tumors of the testis: interrelations, possible cross-reactions and interpretation of beta-HCG level” International Journal of Biological Markers 12(2):55-60 (1997).
Kramer, S. et al. “Gonadotropin levels in ovarian cyst fluids: a predictor of malignancy?” International Journal of Biological Markers 13(3): 165-8 (1998).
Leifke, E. et al., “Does the gonadotrophic axis play a role in the pathogenesis of Sertoli-cell-only syndrome?” International Journal of Andro
DePaoli Alex
Garnick Marc B.
Martha, Jr. Paul M.
Molineaux Christopher J.
Chism B. Dell
DeConti, Jr. Giulio A.
Laccotripe Zacharakis Maria
Lahive & Cockfield LLP
Praecis Pharmaceuticals Inc.
LandOfFree
Methods for treating FSH related conditions with GnRH... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating FSH related conditions with GnRH..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating FSH related conditions with GnRH... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3560335